Apidra insulin glulisine label initial u's approval 2004?

Apidra (insulin glulisine) received its first U.S. Food and Drug Administration (FDA) approval on July 1, 2004.
It is marketed as a rapid‑acting insulin analog for the treatment of both type 1 and type 2 diabetes mellitus, with a label that details dosing, administration, contraindications, and safety information.